Neurocrine Biosciences, Inc. reported $3.37B of revenue over the trailing twelve months, +34% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.37B (to Q2 2026). Net income: $706M, trailing twelve months to Q2 2026. Free cash flow: $866M, trailing twelve months to Q2 2026. Operating margin: 24%, trailing twelve months to Q2 2026.

NBIXNeurocrine Biosciences, Inc.

Healthcare

$142.40-1.9% 1Y

$142.40

$123.1052 weeks$182.85

NBIX as reported

Neurocrine Biosciences, Inc. reported $3.37B of revenue over the trailing twelve months, +34% on the year before. 10 reported series are charted on this page, each one as filed.

$3.37B

Revenue, trailing twelve months · to Q2 2026 · +34% against the twelve months before

Net income: $706M
Net income · +103% year on year · trailing twelve months to Q2 2026
Free cash flow: $866M
Free cash flow · +64% year on year · trailing twelve months to Q2 2026
Operating margin: 24%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NBIX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.37B	+34%	Q2 2026
Net income	$706M	+103%	Q2 2026
EPS	$6.82	+102%	Q2 2026
Gross margin	98%	n/a	Q2 2026
Operating margin	24%	n/a	Q2 2026
Net margin	21%	n/a	Q2 2026
ROE	17%	n/a	Q2 2026
ROA	12%	n/a	Q2 2026
Free cash flow	$866M	+64%	Q2 2026
P/E	20.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.